Quick Answer
NRX Pharmaceuticals, Inc. reported Cash and Equivalents of $7.80 million for fiscal year 2025.
NRX Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.80M | +440.3% |
| 2024 | $1.44M | -68.6% |
| 2023 | $4.59M | -77.1% |
| 2022 | $20.05M | -27.4% |
| 2021 | $27.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.18M | +336.5% | +146.9% |
| June 30, 2025 | $2.91M | +53.3% | -47.5% |
| March 31, 2025 | $5.55M | +320.6% | +284.5% |
| December 31, 2024 | $1.44M | -68.6% | -12.3% |
| September 30, 2024 | $1.65M | -81.5% | -13.3% |
| June 30, 2024 | $1.90M | -87.3% | +43.9% |
| March 31, 2024 | $1.32M | -92.0% | -71.3% |
| December 31, 2023 | $4.59M | -77.1% | -48.4% |
- NRX Pharmaceuticals, Inc. showed an increase of +440.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, NRX Pharmaceuticals, Inc.’s cash and equivalents has declined by 71.8% (from $27.61 million to $7.80 million).
- The most recent figure is from NRX Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: